Drugplain

Vyleesi 1.75 mg/.3mL

bremelanotide · INJECTION · Palatin Technologies

No Recall History
Plain English

Vyleesi is a injection containing bremelanotide at 1.75 mg/.3mL, taken subcutaneous. Manufactured by Palatin Technologies.

Key Facts

Brand Name
Vyleesi
Generic Name
bremelanotide
NDC Code (Product)
80064-141
Manufacturer
Palatin Technologies
Strength
1.75 mg/.3mL
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Marketing Status
Application #
NDA210557
Marketing Start
06/21/2019

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

nausea375 reports
drug ineffective171 reports
headache130 reports
vomiting107 reports
off label use70 reports
flushing65 reports
illness63 reports
adverse drug reaction43 reports
dizziness38 reports
fatigue34 reports

Frequently Asked Questions

What is Vyleesi used for?

Vyleesi contains bremelanotide. It is a injection taken subcutaneous. Consult your doctor for specific uses.

Is Vyleesi a controlled substance?

Vyleesi is not classified as a controlled substance by the DEA.

What is the generic name for Vyleesi?

The generic name for Vyleesi is bremelanotide. There are no other listed brand versions of bremelanotide.

What is the NDC code for Vyleesi 1.75 mg/.3mL?

The NDC (National Drug Code) for Vyleesi 1.75 mg/.3mL is 80064-141, listed by Palatin Technologies.

Product NDC

80064-141

Package NDC

80064-141-02

Other Vyleesi Dosages

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)